DAONIL Tablets 5 Milligram
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
02-04-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
GLIBENCLAMIDE
Available from:
Sanofi-Aventis Ireland Limited
Dosage:
5 Milligram
Pharmaceutical form:
Tablets
Authorization date:
1999-04-01
Summary of Product characteristics
License
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Daonil 5 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Glibenclamide 5mg.
Excipients: contains Lactose Monohydrate 79.0mg
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
White biplane, oblong tablets with ‘LDI’ engraved on each side of scoreline and inverted on one side, the other side is
plain.
The score line present allows the tablet to be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
Daonil is a sulphonylurea hypoglycaemic agent, indicated for the oral treatment of patients with non-insulin dependent
diabetes who respond inadequately to dietary measures alone.
4.2 Posology and method of administration
The dosage of glibenclamide must be the lowest possible dose which is effective.
The usual total daily dosage is 2.5mg to 15mg daily with a usual initial dose of 5mg daily. Weekly adjustments can be
made to increase the dosage to the optimal level. Doses of 10mg or less may be taken as a single dose immediately
before breakfast, but should the daily dose exceed 10mg, the remainder should be taken immediately before the
evening meal.
The elderly usually&#
Read the complete document
